carfloglitazar

Carfloglitazar is a dual peroxisome proliferator-activated receptor (PPAR) agonist, specifically targeting both PPAR alpha and PPAR gamma subtypes. It is a small molecule drug developed for the treatment of metabolic disorders, including type 2 diabetes mellitus, dyslipidemia, non-alcoholic fatty liver disease (NAFLD), and non-alcoholic steatohepatitis (NASH). Carfloglitazar acts as an insulin sensitizer and lipid modulator by activating PPARα to lower triglycerides and improve lipid profiles, while its action on PPARγ enhances insulin sensitivity and glycemic control. The drug has been investigated in preclinical studies for its potential to address both hyperglycemia and dyslipidemia in patients with metabolic syndrome.